Printer Friendly

United States : ImmunoPrecise Antibodies Reports 2017 Annual Results Revenues Up 39% Over Fiscal 2016.

IMMUNOPRECISE ANTIBODIES LTD. (the Company or IPA) yesterday reported its financial results for the fourth quarter ended April 30, 2017 and provides a business update.

ImmunoPrecises focus is on aggressively expanding its share of the research and development antibody global market, delivering its products and services to academic, diagnostic, biotechnology and pharmaceutical customers globally. As of April 30, 2017, the Company had $2,447,476 in working capital to finance its growth initiatives.

During the year ended April 30, 2017 the Company made foundational growth-enabling investments in operational efficiency, improvement to gross margins, new information systems, internet marketing capabilities and lead generation, expansion of laboratory facilities, market research and research and development initiatives aimed at new offerings in the development of humanized antibodies.

Going forward, the Company plans to continue aggressively pursuing strategic initiatives focused on the Companys four stated priority areas:

Growing the core business

Establishing a strong presence in the development of humanized antibodies

Pursuing M&A activities and establishing growth-enabling strategic partnerships

Developing a strong and valuable portfolio of intellectual property assets.

To achieve the best results from its investments the Company has added key scientific and management personnel to its team.

For the year ended April 30, 2017, the Company recorded revenue of $2,630,515 compared to $1,896,118 year ended April 30, 2016. The increased revenue was directly related to the Company being able significantly grow its commercial activities.

The Company recorded a net loss of $5,383,820 during the year ended April 30, 2017, compared to net income of $151,035 for the year ended April 30, 2016. The net loss is comprised of the $3,887,160 listing expenses recorded on completion of the Reverse Takeover-Over (RTO), which is a one-time accounting entry and is not reflective of its ongoing operations. The Company also incurred an operating loss of $1,386,474, which is mostly attributable to non-recurring costs in foundational growth-enabling investments made to pursue strategic initiatives which attracted consulting fees and other one-tie costs such as systems development, business development and operational efficiency aimed at configuring the Company for significant future growth.

These growth-enabling investments include:

Increased staffing and higher laboratory operating costs to accommodate greater levels of activity. The Company also occupied additional space to facilitate expansion, added new equipment and incurred leasehold improvement costs to build a new laboratory that will effectively double the its revenue generating capacity;

To support management and the Board of Directors in exercising oversight, the Company has invested and implemented state-of-the-art information systems for marketing and sales automation and customer relationship management (Salesforce), as well as accounting and financial reporting, resource planning and project management (Financial Force). Comprehensive operational and management reporting capabilities are being instituted with a view to effectively supporting a geographically dispersed organization.

For the year ended April 30, 2017, the Company has made noteworthy progress in its four priority areas identified by management and the Board of Directors. The initiatives include growing the core business, development of humanized antibodies, expansion through an M&A strategy, and investing in acquisition and development of intellectual property assets.

The Company has signed twelve long-term service agreements with new customers and is continuing its niche position in the production of rabbit monoclonal antibodies, a service producing both encouraging revenue and margin growth. The Company is establishing a market presence in the development of humanized antibodies. Antibody humanization is a high margin service that the Company anticipates will see rapidly increasing demand in the next fiscal year onwards.

The Company has completed its first acquisition with the closing of the purchase of U-Protein Express of Utrecht, Netherlands. U-Protein thereby gives IPA a foothold in Europe and is a strong strategic fit with ImmunoPrecise in terms of the intellectual property assets that will result from the combination. In addition, the combination will broaden the joint entitys portfolio of services and geographic reach. U-Protein services will be offered to IPA clients in North America, and IPA services will be offered to U-Protein clients in Europe.

The Company is continuing to strategically invest in developing a strong and valuable portfolio of intellectual property assets for the purpose of securing its profitably in future years. Evaluation and research initiatives are underway in areas such as humanization, immuno-oncology, and development of immune-contraceptive vaccines that will build on its proprietary technology and patent portfolio.

[c] 2017 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
COPYRIGHT 2017 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Article Type:Financial report
Date:Aug 28, 2017
Words:739
Previous Article:France : CHC signs HCare full-by-the-hour contract for H175.
Next Article:France : Airbus Helicopters and IAR deepen strategic partnership on H215M with 15-year agreement.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters